R&D Spotlight: Oncology
David BlakeyAlfie BrennanStuart FarrowPeter Llewellyn-DaviesJim MillenMoritz Haneklaus

Kindly sponsored by Precision for Medicine

  • David Blakey (CSO at FasT Biopharma)

    David Blakey

    CSO at FasT Biopharma
  • Alfie Brennan (Principal Scientist at Evariste)

    Alfie Brennan

    Principal Scientist at Evariste
  • Stuart Farrow (Vice President of Biosciences at Cancer Research Horizons)

    Stuart Farrow

    Vice President of Biosciences at Cancer Research Horizons
  • Peter Llewellyn-Davies (CEO of invIOs GmbH)

    Peter Llewellyn-Davies

    CEO of invIOs GmbH
  • Jim Millen (Director of Kargenera)

    Jim Millen

    Director of Kargenera
  • Moritz Haneklaus (Senior Scientist at Macomics Limited)

    Moritz Haneklaus

    Senior Scientist at Macomics Limited
R&D Spotlight: Vaccines, Infectious Diseases & Microbiome
Richard BungayJeremy SkillingtonKirsty SmittenDouglas ThomsonDavid BrowningNik Sharma
  • Richard Bungay (CEO of Imophoron Ltd)

    Richard Bungay

    CEO of Imophoron Ltd
  • Jeremy Skillington (CEO of Poolbeg Pharma PLC)

    Jeremy Skillington

    CEO of Poolbeg Pharma PLC
  • Kirsty Smitten (CEO of MetalloBio)

    Kirsty Smitten

    CEO of MetalloBio
  • Douglas Thomson (CEO of Pneumagen Ltd)

    Douglas Thomson

    CEO of Pneumagen Ltd
  • David Browning (CEO of Fixed Phage)

    David Browning

    CEO of Fixed Phage
  • Nik Sharma (Co-Founder CEO of BioCorteX)

    Nik Sharma

    Co-Founder CEO of BioCorteX
Lunch & Networking
Technical Update: Quantum Computing & Life Sciences
David GrimmSonali Mohapatra

This session will feature a 15 minute presentation from Sonali Mohapatra, Quantum Innovation Sector Lead at the National Quantum Computing Centre (NQCC) on the potential impact that Quantum Computing will have on drug discovery. Followed by an investment update from David Grimm, Investment Director at Albion VC. David manages the UCL Technology Fund’s Computer and Physical Sciences investment team. Investing in a wide range of exciting deeptech opportunities, including Quantum Computing, Machine Learning and Data Analytics, Cleantech, Medtech, Edtech and Hardware.

There will be the opportunity for audience Q&A after the presentations.

  • David Grimm (Investment Director of UCL Technology Fund)

    David Grimm

    Investment Director of UCL Technology Fund
  • Sonali Mohapatra (Quantum Innovation Sector Lead at National Quantum Computing Centre)

    Sonali Mohapatra

    Quantum Innovation Sector Lead at National Quantum Computing Centre
R&D Spotlight: Platforms
Robert GrundyAneesh Karatt VellattMichael RobertsDaniel Ives
  • Robert Grundy (Vice President, Business Development at Intelligent OMICS)

    Robert Grundy

    Vice President, Business Development at Intelligent OMICS
  • Aneesh Karatt Vellatt (CSO and Co-founder of Maxion Therapeutics)

    Aneesh Karatt Vellatt

    CSO and Co-founder of Maxion Therapeutics
  • Michael Roberts (CEO of Chromatin Bioscience)

    Michael Roberts

    CEO of Chromatin Bioscience
  • Daniel Ives (CEO and Founder of Shift Bioscience)

    Daniel Ives

    CEO and Founder of Shift Bioscience
R&D Spotlight: Medtech
Alex BatchelorAlex CharitouGeorge FrodshamVictor HarabariAntoine PouppezNick SkaerMikesh Udani
  • Alex Batchelor (CEO of Pictura Bio Ltd)

    Alex Batchelor

    CEO of Pictura Bio Ltd
  • Alex Charitou (Partner | Life Sciences at EY)

    Alex Charitou

    Partner | Life Sciences at EY
  • George Frodsham (CEO of MediSieve Limited)

    George Frodsham

    CEO of MediSieve Limited
  • Victor Harabari (Founder and CEO of Cardiocrown)

    Victor Harabari

    Founder and CEO of Cardiocrown
  • Antoine Pouppez (CEO of NeuroClues)

    Antoine Pouppez

    CEO of NeuroClues
  • Nick Skaer (CEO of Orthox Limited)

    Nick Skaer

    CEO of Orthox Limited
  • Mikesh Udani (CEO of Albus Health)

    Mikesh Udani

    CEO of Albus Health
R&D Spotlight: Rare Diseases
Rebecca AbramLisa ConteAnna Perdrix RosellJonathan ReesDan Williams

Kindly sponsored by FUJIFILM Diosynth Biotechnologies

  • Rebecca Abram (Director, Strategic Technical Marketing of Fujifilm Diosynth Biotechnologies)

    Rebecca Abram

    Director, Strategic Technical Marketing of Fujifilm Diosynth Biotechnologies
  • Lisa Conte (President/CEO Jaguar Health and Chairman, BOD, Napo Therapeutics of Jaguar Health Inc.)

    Lisa Conte

    President/CEO Jaguar Health and Chairman, BOD, Napo Therapeutics of Jaguar Health Inc.
  • Anna Perdrix Rosell (co-CEO and co-founder of Sixfold Bioscience)

    Anna Perdrix Rosell

    co-CEO and co-founder of Sixfold Bioscience
  • Jonathan Rees (CEO of MitoRx Therapeutics Limited)

    Jonathan Rees

    CEO of MitoRx Therapeutics Limited
  • Dan Williams (CEO of SynaptixBio)

    Dan Williams

    CEO of SynaptixBio
R&D Spotlight: Neuroscience
Jenny BarnettChristophe GaudinPeter HamleyJerome ParcqJames PeachSimon Loiodice
  • Jenny Barnett (CEO of Monument Therapeutics Limited)

    Jenny Barnett

    CEO of Monument Therapeutics Limited
  • Christophe Gaudin (CEO of Op2lysis)

    Christophe Gaudin

    CEO of Op2lysis
  • Peter Hamley (Chief Scientific Officer at Samsara Therapeutics Ltd)

    Peter Hamley

    Chief Scientific Officer at Samsara Therapeutics Ltd
  • Jerome Parcq (Co-Founder of Op2lysis)

    Jerome Parcq

    Co-Founder of Op2lysis
  • James Peach (CEO of Human Centric DD Ltd)

    James Peach

    CEO of Human Centric DD Ltd
  • Simon Loiodice (Co-Founder and CEO of Karla Tx)

    Simon Loiodice

    Co-Founder and CEO of Karla Tx
R&D Spotlight: Oncology
Francesca RapinoGraeme RogersAlan RothSzabolcs NagyClare WareingIgor Matushansky

Kindly sponsored by Ipsen

  • Francesca Rapino (COO at Theratrame)

    Francesca Rapino

    COO at Theratrame
  • Graeme Rogers (Chief Scientific Officer at Omideon)

    Graeme Rogers

    Chief Scientific Officer at Omideon
  • Alan Roth (CEO of Oxford Drug Design)

    Alan Roth

    CEO of Oxford Drug Design
  • Szabolcs Nagy (Founder, CEO of Turbine AI)

    Szabolcs Nagy

    Founder, CEO of Turbine AI
  • Clare Wareing (Founder & Chief Executive Officer of Cumulus Oncology)

    Clare Wareing

    Founder & Chief Executive Officer of Cumulus Oncology
  • IM

    Igor Matushansky

    Global Head, Oncology Therapeutic Area at Ipsen
Technical Update: Targeted Protein DegradationProgress, Direction and Prospects
Sheelagh Frame
Lunch & Networking
R&D Spotlight: Inflammatory Disease
Salman RahmanJason RuttKirsty SempleMark PeakmanMark Dowling

Kindly sponsored by Sanofi

  • Salman Rahman (CEO of Vasgen Ltd)

    Salman Rahman

    CEO of Vasgen Ltd
  • Jason Rutt (Founder and CEO of Azadyne)

    Jason Rutt

    Founder and CEO of Azadyne
  • Kirsty Semple (CEO of SENISCA Ltd)

    Kirsty Semple

    CEO of SENISCA Ltd
  • Mark Peakman (Head of Autoimmunity Cluster, Immunology & Inflammation Research at Sanofi)

    Mark Peakman

    Head of Autoimmunity Cluster, Immunology & Inflammation Research at Sanofi
  • Mark Dowling (Head External Innovation Immunology at Sanofi)

    Mark Dowling

    Head External Innovation Immunology at Sanofi
R&D Spotlight: Cell & Gene Therapy
James Barwick-SilkSimon ChandlerCarin IngemarsdotterCarolyn PorterVlad SeitanSapan Gandhi

Kindly sponsored by Syneos Health

  • James Barwick-Silk (Director, Scientific Strategy, Cell & Gene Therapy of Syneos Health)

    James Barwick-Silk

    Director, Scientific Strategy, Cell & Gene Therapy of Syneos Health
  • Simon Chandler (CEO of Rinri Therapeutics Ltd.)

    Simon Chandler

    CEO of Rinri Therapeutics Ltd.
  • Carin Ingemarsdotter (Co-Founder and COO of Spliceor Therapeutics)

    Carin Ingemarsdotter

    Co-Founder and COO of Spliceor Therapeutics
  • Carolyn Porter (CEO of CytoSeek)

    Carolyn Porter

    CEO of CytoSeek
  • Vlad Seitan (CSO at Laverock Therapeutics)

    Vlad Seitan

    CSO at Laverock Therapeutics
  • Sapan Gandhi (Founder of Drishti Discoveries)

    Sapan Gandhi

    Founder of Drishti Discoveries

BioTrinity Panels, Interviews & Keynotes


We aim to deliver a well-rounded programme of presentations, discussions, and debate around a variety of subject matters prevalent in the life sciences industry today. We include a mix of scientific focused topics, which either address the latest innovation and research, or matters that are popular and much talked about in the current mainstream landscape, along with pertinent updates on the financing and investment landscapes, as well as regulatory and legislative updates from leading voices and decision makers.


We cover a lot of ground, and the range is broad, but we aim to support our delegates by delivering a programme that is digestible, useful, and thought-provoking.

Each R&D spotlight will include 5 x 10 minute company presentations from the most innovative companies working in; Oncology, Infectious Diseases, Microbiome, Rare Diseases, Medtech, Neuroscience, Inflammatory Disease and Cell and Gene Therapy. If you are a company seeking Series A investment or to partner assets, BioTrinity is for you! Contact events@obn.org.uk

Detailed below is an outline of all of the sessions, if you have any queries then please email events@obn.org.uk